<DOC>
	<DOCNO>NCT01408290</DOCNO>
	<brief_summary>The purpose study determine immunogenicity , tolerability dose-effect relationship one 0.5 mL intramuscular ( IM ) injection four FLUVAL AB-like trivalent influenza vaccine contain either 3.5μgHA , 6μgHA,9μgHA 15μgHA seasonal A/H1N1 , A/H3N2 B influenza antigens adult elderly people .</brief_summary>
	<brief_title>Safety Immunogenicity Study Fluval AB-Like Flu Vaccines With 3.5 , 6 , 9 15 μg HA Adult Elderly People</brief_title>
	<detailed_description>Primary immunogenicity objectives - To assess immunogenicity one 0.5 mL intramuscular ( IM ) injection four FLUVAL AB-like trivalent influenza vaccine contain either 3.5μgHA , 6μgHA , 9μgHA 15μgHA seasonal A/H1N1 , A/H3N2 B influenza antigen , measure haemagglutination inhibition ( HI ) test 21 day vaccination compliance requirement current European Union recommendation determine CPMP/BWP/214/96 . - To determine dose-effect relationship one 0.5 mL IM injection four FLUVAL AB-like trivalent influenza vaccine contain either 3.5μgHA , 6μgHA , 9μgHA 15μgHA seasonal A/H1N1 , A/H3N2 B influenza antigens immune response provoke 21 day vaccination term pre- postimmunization HA titer measure HI test . Secondary immunogenicity objectives - To assess immunogenicity one 0.5 mL IM injection four FLUVAL AB-like trivalent influenza vaccine contain either 3.5μgHA , 6μgHA , 9μgHA 15μgHA seasonal A/H1N1 , A/H3N2 B influenza antigen , measure HI test 14 day vaccination compliance requirement current European Union recommendation determine CPMP/BWP/214/96 . - To find high dose FLUVAL AB-like trivalent influenza vaccine among 3.5μgHA , 6μgHA 9μgHA response differs dose 15μgHA term post-immunization HA titer measure HI test 21 day vaccination . - To find high dose FLUVAL AB-like trivalent influenza vaccine among 3.5μgHA , 6μgHA 9μgHA response differs dose 15μgHA term post-immunization HA titer measure HI test 14 day vaccination . - To find high dose FLUVAL AB-like trivalent influenza vaccine among 3.5μgHA , 6μgHA 9μgHA response differs dose 15μgHA term percentage subject achieve seroconversion significant increase antibody titer day 21 vaccination . - To find high dose FLUVAL AB-like trivalent influenza vaccine among 3.5μgHA , 6μgHA 9μgHA response differs dose 15μgHA term percentage subject achieve seroconversion significant increase antibody titer day 14 vaccination . - To find high dose FLUVAL AB-like trivalent influenza vaccine among 3.5μgHA , 6μgHA 9μgHA response differs dose 15μgHA term Day 21/Day 0 geometric mean titer ratio ( GMTRs ) determine HI . - To find high dose FLUVAL AB-like trivalent influenza vaccine among 3.5μgHA , 6μgHA 9μgHA response differs dose 15μgHA term Day 14/Day 0 geometric mean titer ratio ( GMTRs ) determine HI . Safety tolerability objective - To evaluate safety administration one 0.5 mL IM injection four FLUVAL AB-like trivalent influenza vaccine contain either 3.5μgHA , 6μgHA,9μgHA 15μgHA seasonal A/H1N1 , A/H3N2 B influenza antigen .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>male female adult volunteer age 18 year old , mentally competent , able understand comply study requirement , willing able give write informed consent prior initiation study procedure , good health ( determined clinical judgement investigator basis medical history exist medical condition ) stable medical condition . Subjects exclude know , adequately treat , clinically significant organ systemic disease ( e.g . asthma diabetes ) , , opinion investigator , significance disease compromise subject 's participation study . Female subject age 18 60 year ( i.e . participant childbearing potential ) negative result urine pregnancy test prior vaccination agree use acceptable contraception method abstinence throughout trial become pregnant duration study . Absence existence exclusion criterion . Pregnancy , breastfeed positive urine pregnancy test baseline prior vaccination . Female subject able bear child willing use acceptable contraception method duration study . Hypersensitivity egg , chicken protein , thiomersal , formaldehyde , gentamycin , ciprofloxacin , neomycin component vaccine ; History anaphylactic shock neurological symptom sign follow administration vaccine ; History GuillainBarré syndrome ; Serious disease , cancer , autoimmune disease , advance arteriosclerotic disease , complicate diabetes mellitus , acute progressive hepatic disease , acute progressive renal disease , congestive heart failure ; Immunosuppressive therapy within past 36 month ; Concomitant corticosteroid therapy , include highdose inhaled corticosteroid ; Receipt immunostimulants ; Receipt parenteral immunoglobulin , blood product and/or plasma derivates within past 3 month ; Suspected known HIV , HBV HCV infection ; Acute disease and/or axillary temperature ≥37oC within past 3 day ; Vaccine therapy within past 4 week ; Influenza vaccination ( kind ) within past 6 month ; Experimental drug therapy within past 4 week ; Concomitant participation another clinical study ; Any condition , opinion investigator , may interfere evaluation study ; Past current psychiatric disease subject upon judgement investigator may effect objective decisionmaking subject ; Alcohol drug abuse subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>seasonal</keyword>
	<keyword>prevention</keyword>
	<keyword>influenza</keyword>
	<keyword>infection</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>vaccine</keyword>
	<keyword>influenza human</keyword>
</DOC>